Lustberg, Daniel
Iannitelli, Alexa F.
Tillage, Rachel P.
Pruitt, Molly
Liles, L. Cameron
Weinshenker, David
Funding for this research was provided by:
National Institute on Aging (AG061175)
National Institute of Neurological Disorders and Stroke (NS102306)
National Institute on Drug Abuse (DA038453)
National Institute of General Medical Sciences (GM8602-22)
National Institute of Mental Health (MH116622)
Article History
Received: 27 November 2019
Accepted: 26 March 2020
First Online: 20 April 2020
Compliance with ethical standards
:
: DW is co-inventor on a patent concerning the use of selective dopamine β-hydroxylase inhibitors for the treatment of cocaine dependence (US-2010-0105748-A1; “Methods and Compositions for Treatment of Drug Addiction”). The other authors declare no conflicts of interest.